Cantor Fitzgerald Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $103
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) but lowers the price target from $108 to $103.

February 21, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald maintains an Overweight rating on Axsome Therapeutics but lowers the price target from $108 to $103.
While the maintenance of an Overweight rating suggests continued confidence in Axsome Therapeutics' fundamentals and growth prospects, the reduction in the price target could reflect adjustments in valuation models or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100